Subscribe to RSS
DOI: 10.1055/s-2006-957185
© Georg Thieme Verlag KG Stuttgart · New York
Immunintervention bei neu diagnostiziertem Typ-1-Diabetes
Immunointervention in newly diagnosed type 1 diabetesPublication History
eingereicht: 26.6.2006
akzeptiert: 26.10.2006
Publication Date:
29 November 2006 (online)

Zusammenfassung
Typ-1-Diabetes (T1D) ist die Folge eines T-Zell-vermittelten Autoimmunprozesses, der zur Zerstörung der pankreatischen Betazellen führt. Auch nach der klinischen Manifestation trägt eine körpereigene Restproduktion von Insulin wesentlich zu einer stabileren und besseren Blutzuckereinstellung bei und somit auch dazu, das Auftreten von diabetischen Folgeerkrankungen hinauszuzögern oder zu verhindern.
Diese Übersicht stellt die Studien zur Immunintervention bei neumanifestem T1D dar, die derzeit in deutschen Zentren auf nationaler oder internationaler Ebene durchgeführt werden. Primärer Endpunkt aller Studien ist der Erhalt der Betazell-Reserve, gemessen am basalen und stimulierten C-Peptid. Sekundäre Endpunkte umfassen HbA1c, Insulinbedarf, Nüchternblutzucker sowie das zelluläre und humorale Immunmonitoring. 1) Die Wirksamkeit des synthetischen Peptids DiaPep277 soll in einer placebokontrollierten, doppelblinden Phase III Studie an 400 Teilnehmern in elf Ländern verifiziert werden. 2) In München und Mailand werden derzeit Mycophenolat mofetil und Daclizumab (MMF-DZB), zwei aus der Transplantationsmedizin bekannte Wirkstoffe, kombiniert. 3) In München läuft eine Studie zur Immunintervention mit 1,25-Dihydroxy-Vitamin D3 mit 40 Teilnehmern. 4) In Belgien, Paris und München werden 80 Teilnehmer einer Phase II-Studie mit dem aglykosylierten, nicht mitogenen monoklonalen CD3-Antikörper YTH 12.5 (ChAgly CD3) nach nur 6-tägiger Infusion bereits im 4. Jahr nachbeobachtet. Eine Zwischenauswertung nach 18 Monaten zeigte sich erfolgreich. 5) Eine Phase II Studie mit dem alterierten Peptidliganden APL-NBI-6024 zeigte keinen Effekt auf die Betazell-Restfunktion.
Summary
Type 1 diabetes (T1D) ist the result of a T-cell mediated autoimmune process leading to destruction of pancreatic beta cells. Even after clinical manifestation of the disease, a residual secretion of endogenous insulin essentially helps to maintain better metabolic control and also to delay or prevent the onset of complications.
This review describes intervention trials in newly diagnosed T1D which are currently performed in German diabetes centers on a national or international base. Primary endpoint in all these studies is the preservation of the beta cell reserve, indicated by basal and stimulated C-peptide. Secondary endpoints include HbA1c levels, insulin requirements, fasting blood glucose levels, and monitoring of cellular and humoral immune responses. 1) The effectiveness of the synthetic peptide DiaPep277 will be verified in a double-blind placebo-controlled phase III study including 400 participants in 11 countries. 2) In Munich and Milan an ongoing study combines mycophenolate mofetil and daclizumab (MMF-DZB). Both drugs are known from transplant medicine. 3) In Munich, a trial tests the immunointervention with 1,25-dihydroxyvitamin D3 in 40 subjects. 4) In Belgium, Paris and Munich, 80 participants in a phase II study who were given the aglycosylated, non-mitogenic monoclonal anti-CD3 antibody YTH 12.5 (ChAgly CD3) intravenously over 6 days, have now been followed-up for nearly 4 years. A first analysis after 18 months showed a quite successful therapy. 5) A phase II trial with the altered peptide ligand APL-NBI-6024 did not show any effect on betacell residual function.
Schlüsselwörter
Diabetes mellitus - Immunintervention - Betazellfunktion - C-Peptid - Prävention
Key words
diabetes mellitus - immunointervention - beta cell function - C-peptide - prevention
Literatur
- 1
Ablamunits V, Elias D, Reshef T, Cohen I R.
Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment.
J Autoimmun.
1998;
11
73-81
MissingFormLabel
- 2
Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen I R.
T-cell responses of type I diabetes patients and healthy individuals to human hsp60
and its peptides.
J Autoimmun.
1999;
12
121-129
MissingFormLabel
- 3
Allen H F, Klingensmith G J, Jensen P, Simoes E, Hayward A, Chase H P.
Effect of Bacillus Calmette-Guerin Vaccination on New Onset Type 1 Diabetes.
Diabetes Care.
1999;
22
1703-1707
MissingFormLabel
- 4
Alleva D G, Maki R A, Putnam A L. et al .
Immunomodulation in Type 1 diabetes by NBI-6024, an Altered Peptide Ligand of the
Insulin B(9 - 23) Epitope.
Scand J Immunol.
2006;
63
59-69
MissingFormLabel
- 5
Assan R, Feutren G, Debray-Sachs M. et al .
Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes
mellitus.
Lancet.
1985;
1
67-71
MissingFormLabel
- 6
Baumgartl H J, Standl E, Schmidt-Gayk H, Kolb H J, Janka H U, Ziegler A G.
Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1
(insulin-dependent) diabetes mellitus.
Diabetes Res.
1991;
16
145-148
MissingFormLabel
- 7
Bottazzo G F, Dean B M, McNally J M, MacKay E H, Swift P G, Gamble D R.
In situ characterization of autoimmune phenomena and expression of HLA molecules in
the pancreas in diabetic insulitis.
N Engl J Med.
1985;
313
353-360
MissingFormLabel
- 8
Chase H P, Butler-Simon N, Garg S, McDuffie M, Hoops S L, O’Brien D.
A trial of nicotinamide in new-onset type I (insulin-dependent) diabetes mellitus.
Diabetologia.
1990;
33
444-446
MissingFormLabel
- 9
Chatenoud L, Primo J, Bach J F.
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice.
J Immunol.
1997;
158
2947-2954
MissingFormLabel
- 10
David D A, Gaur A, Jin L.
Immunological characterization and therapeutic activity of an altered peptide ligand,
NBI-6024, based on the immunodominant Type 1 Diabetes autoantigen Insulin B-Chain
(9 - 23) Peptide.
Diabetes.
2002;
51
2126-2134
MissingFormLabel
- 11
The Diabetes Control and Complications Trial Research Group .
Effect of intensive therapy on residual b-cell function patients with type 1 diabetes
in the diabetes control a complications trial. A randomized, controlled trial.
Ann Intern Med.
1998;
128
517-523
MissingFormLabel
- 12
Elias D, Markovits D, Rehef T, Van der Zee R, Cohen I R.
Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/LT) mouse
by a 65-kDa heat shock protein.
Proc Natl Acad Sci USA.
1990;
87
1576-1580
MissingFormLabel
- 13
Elias D, Meilin A, Ablamunits V. et al .
Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and down-regulates
autoimmunity to various beta-cell antigens.
Diabetes.
1997;
46
758-764
MissingFormLabel
- 14
Elias D, Reshef T, Birk O S, Van der Zee R, Walker M D, Cohen I R.
Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65
kDa heat shock protein.
Proc Natl Acad Sci USA.
1991;
88
3088-3091
MissingFormLabel
- 15
Foulis A K, Liddle C N, Farquharson M A, Richmond J A, Weir R S.
The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus:
a 25-year review of deaths in patients under 20 years of age in the United Kingdom.
Diabetologia.
1986;
29
267-274
MissingFormLabel
- 16
Greenbaum C J, Harrison L C. on behalf of the Immunology of Diabetes Society .
Guidelines for intervention trials in subjects with newly-diagnosed type 1 diabetes.
Diabetes.
2003;
52
1059-1065
MissingFormLabel
- 17
Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L.
A ,25-Dihydroxyvitamin D3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice.
Diabetes.
2002;
51
1367-1374
MissingFormLabel
- 18
Hao L, Calcinaro F, Gill R G, Eugui E M, Allison A C, Lafferty K J.
Facilitation of specific tolerance Iduction in adult mice by RS-61 443.
Transplantation.
1992;
53
590-595
MissingFormLabel
- 19
Hao L, Chan S M, Lafferty K.
Mycophenolate mofetil can prevent the development of diabetes in BB Rats.
Ann New York Acad Sciences.
1993;
696
328-332
MissingFormLabel
- 20
Hayes C E, Nashold F E, Spach K M, Pedersen L B.
The immunological functions of the vitamin D endocrine system.
Cell Mol Biol.
2003;
49
277-300
MissingFormLabel
- 21
Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler A G.
Early Appearance of Islet Autoantibodies Predicts Childhood Type 1 Diabetes in Offspring
of Diabetic Parents.
Ann Internal Med.
2004;
140
882-886
MissingFormLabel
- 22
Hummel M, Ziegler A G, Roth R.
Psychological impact of childhood islet autoantibody testing in families participating
in the BABYDIAB study.
Diabetic Medicine.
2004;
21
324-328
MissingFormLabel
- 23
Itoh N, Hanafusa T, Miyazaki A. et al .
Mononuclear cell infiltration and its relation to the expression of major histocompatibility
complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed
insulin-dependent diabetes mellitus patients.
J Clin Invest.
1993;
92
2313-2322
MissingFormLabel
- 24
Johnson S B, Tercyak K P.
Psychological impact of islet cell antibody screening for IDDM on children, adults,
and their family members.
Diabet Care.
1995;
18
1370-1372
MissingFormLabel
- 25
Jones E L, Epinette W W, Hackney V C, Menendez L, Frost P.
Treatment of psoriasis with oral mycophenolic acid.
J Invest Dermatol.
1975;
65
537-542
MissingFormLabel
- 26
Keymeulen B, Vandemeulebroucke E, Ziegler A G. et al .
Insulin needs after CD3-Antibody therapy in New-Onset Type 1 Diabetes.
N Engl J Med.
2005;
352
2598-2608
MissingFormLabel
- 27
Kobashigawa J A, Katznelson S, Laks H. et al .
Effect of pravastatin on outcomes after cardiac transplantation.
N Engl J Med.
1995;
333
621-627
MissingFormLabel
- 28
Kolb H, Gale E AM.
Does partial preservation of residual beta-cell function justify immune intervention
in recent onset Type I diabetes?.
Diabetologia.
2001;
44
1349-1353
MissingFormLabel
- 29
Kwak B, Mulhaupt F, Myit S, Mach F.
Statins as a newly recognized type of immunomodulator.
Nat Med.
2000;
6
1399-1402
MissingFormLabel
- 30
Martin S, Schernthaner G, Nerup J. et al .
Follow-up of cyclosporin. A treatment in type 1 (insulin-dependent) diabetes mellitus:
lack of long-term effects.
Diabetologia.
1991;
34
429-434
MissingFormLabel
- 31
Pozzilli P, Manfrini S, Crino A. et al .
Low levels of 25-hydroxyvitamin D3 and 1,25-di- hydroxyvitamin D3 in patients with
newly diagnosed Type 1 Diabetes.
Horm Metab Res.
2005;
37
680-683
MissingFormLabel
- 32
Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen I R.
-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock
protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
Lancet.
2001;
358
1749-1753
MissingFormLabel
- 33
Riachy R, Vandewalle B, Moerman E. et al .
1,25-di-hydroxyvitamin D3 protects human pancreatic islets against cytokine-induced
apoptosis via down-regulation of the fas receptor.
Apoptosis.
2006;
11
151-159
MissingFormLabel
- 34
Saggese G, Frederico G, Balestri M, Torriolo A.
Calcitriol inhibits the PHA-induced production of IL-2 and IFN-gamma and the proliferation
of human peripheral blood leukocytes while enhancing the surface expression of HLA
class II molecules.
J Endocrinol Invest.
1989;
12
329-335
MissingFormLabel
- 35
Schiff M.
Emerging treatments for rheumatoid arthritis.
Am J Med.
1997;
102 1A
11S-15S
MissingFormLabel
- 36
Schnell O, Eisfelder B, Standl E, Ziegler A G.
High-dose intravenous insulin infusion versus intensive insulin treatment in newly
diagnosed IDDM.
Diabetes.
1997;
46
1607-1611
MissingFormLabel
- 37
Shah S C, Malone J I, Simpson N E.
A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent
diabetes mellitus.
N Engl J Med.
1989;
320
550-554
MissingFormLabel
- 38
Walter M, Albert E, Conrad M, Keller E, Hummel M, Ferber K, Barratt B J, Todd J A, Ziegler A G, Bonifacio E.
IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of type 1
diabetes and associated autoimmunity.
Diabetologia.
2003;
46
712-720
MissingFormLabel
- 39
Walter M, Ziegler A G.
Anti-CD3-Antikörper reduzieren langfristig den Insulinbedarf bei neumanifestem Typ-1-Diabetes.
Diabetes Stoffwechsel.
2005;
14
219-220
MissingFormLabel
- 40
Weitz-Schmidt G, Welzenbach K, Brinkmann V. et al .
Statins selectively inhibit leukocyte function antigen-1 by binding a novel regulatory
integrin site.
Nat Med.
2001;
7
687-692
MissingFormLabel
- 41
White J R, Campbell R K, Hirsch I.
Insulin analogues.
Postgrad Med.
1997;
2
101
MissingFormLabel
Thomas Kaupper
Institut für Diabetesforschung
Kölner Platz 1
80804 München
Phone: 089/30793114
Fax: 089/3081733
Email: prevent.diabetes@lrz.uni-muenchen.de